PreludeDx Presents New Data Demonstrating Utility of DCISionRT to De-escalate Radiation Therapy for Women with DCIS itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, presented data on the use of DCISionRT® to.
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant radiotherapy group (group 1) and non-radiotherapy group (group 2). 2. 2% of patients in the total cohort underwent mastectomy and all of them were in the non-radiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant breast radiotherapy is a common practice in early
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant radiotherapy group (group 1) and non-radiotherapy group (group 2). 2. 2% of patients in the total cohort underwent mastectomy and all of them were in the non-radiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant breast radiotherapy is a common practice
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that.